Subbiah V - Search Results

1

Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma.

Janku F, Park H, Call SG, Madwani K, Oki Y, Subbiah V, Hong DS, Naing A, Velez-Bravo VM, Barnes TG, Hagemeister FB, Falchook GS, Karp DD, Wheler JJ, Piha-Paul SA, Garrido-Laguna I, Shpall EJ, Fayad LE, Neelapu SS, Meric-Bernstam F, Kurzrock R, Fanale MA. Janku F, et al. Among authors: subbiah v. Clin Cancer Res. 2020 Nov 1;26(21):5579-5587. doi: 10.1158/1078-0432.CCR-20-1215. Epub 2020 Oct 14. Clin Cancer Res. 2020. PMID: 33055173 Clinical Trial.

2

Resistance to mammalian target of rapamycin inhibitor therapy in perivascular epithelioid cell tumors.

Subbiah V, Trent JC, Kurzrock R. Subbiah V, et al. J Clin Oncol. 2010 Aug 20;28(24):e415. doi: 10.1200/JCO.2010.29.4678. Epub 2010 Jun 21. J Clin Oncol. 2010. PMID: 20567010 No abstract available.

3

Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures.

Subbiah V, Naing A, Brown RE, Chen H, Doyle L, LoRusso P, Benjamin R, Anderson P, Kurzrock R. Subbiah V, et al. PLoS One. 2011 Apr 6;6(4):e18424. doi: 10.1371/journal.pone.0018424. PLoS One. 2011. PMID: 21494688 Free PMC article.

4

Phase 1 clinical trials for sarcomas: the cutting edge.

Subbiah V, Kurzrock R. Subbiah V, et al. Curr Opin Oncol. 2011 Jul;23(4):352-60. doi: 10.1097/CCO.0b013e3283477a94. Curr Opin Oncol. 2011. PMID: 21519259 Review.

5

Insulin-like growth factor 1 receptor (IGF-1R) inhibitor: another arrow in the quiver - Will it hit the moving target?

Subbiah V, Angelo LS, Kurzrock R. Subbiah V, et al. Expert Opin Investig Drugs. 2011 Nov;20(11):1471-7. doi: 10.1517/13543784.2011.619978. Epub 2011 Sep 21. Expert Opin Investig Drugs. 2011. PMID: 21936711

6

Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside.

Subbiah V, Slopis J, Hong DS, Ketonen LM, Hamilton J, McCutcheon IE, Kurzrock R. Subbiah V, et al. J Clin Oncol. 2012 Feb 10;30(5):e64-8. doi: 10.1200/JCO.2011.38.2614. Epub 2011 Dec 27. J Clin Oncol. 2012. PMID: 22203760 Free PMC article. Clinical Trial. No abstract available.

7

Ewing's sarcoma: overcoming the therapeutic plateau.

Subbiah V, Kurzrock R. Subbiah V, et al. Discov Med. 2012 Jun;13(73):405-15. Discov Med. 2012. PMID: 22742646 Free PMC article.

8

Targeting the apoptotic pathway in chondrosarcoma using recombinant human Apo2L/TRAIL (dulanermin), a dual proapoptotic receptor (DR4/DR5) agonist.

Subbiah V, Brown RE, Buryanek J, Trent J, Ashkenazi A, Herbst R, Kurzrock R. Subbiah V, et al. Mol Cancer Ther. 2012 Nov;11(11):2541-6. doi: 10.1158/1535-7163.MCT-12-0358. Epub 2012 Aug 20. Mol Cancer Ther. 2012. PMID: 22914439 Free PMC article.

9

A tale of two histiocytic disorders.

Janku F, Munoz J, Subbiah V, Kurzrock R. Janku F, et al. Among authors: subbiah v. Oncologist. 2013;18(1):2-4. doi: 10.1634/theoncologist.2012-0440. Epub 2013 Jan 8. Oncologist. 2013. PMID: 23299771 Free PMC article.

10

Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials.

Subbiah IM, Subbiah V, Tsimberidou AM, Naing A, Kaseb AO, Javle M, Fu S, Hong DS, Piha-Paul S, Wheler JJ, Hess KR, Janku F, Falchook GS, Wolff RA, Kurzrock R. Subbiah IM, et al. Among authors: subbiah v. Oncotarget. 2013 Jan;4(1):156-65. doi: 10.18632/oncotarget.832. Oncotarget. 2013. PMID: 23391555 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

579 results

Search Page